Pharmacopeia — Pharmacopeia Drug Discovery — Shareholder Meeting (May 2005)
17 slides from Pharmacopeia's shareholder meeting presentation, May 5, 2005

Slide 1: Annual Meeting, Princeton, New Jersey, May 5th, 2005
HARMACOPEIA RUG DISCOVERY Annual Meeting Princeton, New Jersey May 5th, 2005

Slide 2: Forward-Looking Statements
Forward-Looking Statemen When used anywhere in this presentation, the words "expects," "believes," “articipates," "estimates" and similar expressions are intended to identity forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operatin

Slide 3: Pharmacopeia Drug Discovery
PHARMACOPEIA DRUG DISCOVERY Pharmacopeia Drug Discovery, Inc. is a biopharmaceutical company, focused on the creation of new small molecule therapeutics to address significant unmet medical needs PHARMACOPEIA

Slide 4: Pharmacopeia Overview: PCOP Investment Drivers
Pharmacopeia Overview PCOP Investment Drivers + Comprehensive, integrated drug discovery capabilities + Proven track record of development success — 10 therapeutic candidates with 6 pharma collaborators + Future ‘annuity’ from broad partnered portfolio + Growing portfolio of small molecule drug cand

Slide 5: Business Strategy
Business Strategy Building a Clinical Portfolio + Discover and develop candidates to clinical validation * Build a portfolio of high value candidates fo treat immunological diseases « Partner at high value inflection points B&B PHARMACOPEIA

Slide 6: Drugs in the Pipeline
Drugs in the el Advance intern pipeline to the « + ADME Tox * early product | * intellectual p 2 Evolve succes: collaboration 2005-2006 2007+ BB PHARMACOPEIA

Slide 7: Validated Discovery Platform
alidated Discovery Platform Lead Lead Pre-clinical Discovery 7) HtT9 Lead) optimization | Developmer Phase | Phase ll > BB PHARMACOPEIA

Slide 8: Successful Discovery Business
‘cessful Discovery Busines 10/5104 = Pharmacopeia Achieves Preclinical Development Candidate Milestone in Collaboration with Schering-Plough 10/25/04 Pharmacopeia Announces Expanded Collaboration with Neurocrine 10/26/04 Biovitrum AB and Pharmacopeia Form Strategic Research Alliance 1119104 Pharmaco

Slide 9: Milestones today and royalties in the future
Milestones today and royalties in the future Preciinica! Glinied Phrase Lead Now Program | Partner | censration | Ortimization | Cevelopment [| u wo | Pied Posio4s | Rheumatoid | Bristol Myer mee (tt Psancea | Aathmasiieay | Daiichi sree vu Pese2as | Respiratory | Soheine Plough > 9201622 | intammat

Slide 10: Strategy
Strategy + Evolve the successful collaboration drug discovery business — capture an increasing share of the downstream return + Advance and expand the portfolio of wholly- owned therapeutic product programs — rapidly bring drug candidates to clinical validation — partner at high value inflection poi

Slide 11: Link to searchable text of slide shown above
Link to searchable text of slide shown above

Slide 12: Robust Pipeline
Robust Pipeline Multiple Product Partnered Opportunities Partnered + Internal Lead Optimization 18 Lead Discovery 21 Screening/Screen Development BB PHARMACOPEIA

Slide 13: Therapeutic Focus
Therapeutic Foc! Rheumatoid Arthritis Multiple Sclerosis Inflammatory Ulcerative Colitis Bowel Disease Single target modulates multiple diseases BB PHARMACOPEIA

Slide 14: Large Market Opportunities
Large Market Opportunities Market Size for Selected Inflammation Therapeutics US Market Only 2003 Revenues 8.0 TA 70 6.0 5 4g we a5 £ 5 240 a a 3.0 20 10 0.0 Asthma Rheumatoid Arthritis Psoriasis Inflammatory Bowel Diseases Source: Defined Health, 2004 BB PHARMACOPEIA

Slide 15: PCOP Investment Drivers: Most Advanced Internal Programs
PCOP Investmen ve Most Advanced Internal Programs * p38 kinase inhibitors + Phase | partnered with Bristol-Myers Squibb + Rheumatoid arthritis and other inflammatory diseases + Potentially best in class * avp3 / avp5 blockers + Pharmacopeia wholly-owned + Cancer, ocular and inflammation + Preclinica

Slide 16: Financial Summary
Financial Summa * 2004 Financial Data $24.4 MM in revenue $11.5 MM net loss, excluding restructuring charge $40.9 MM in cash on December 31, 2004 Cash burn May 1, 2004 — December 31, 2004 = $5.9MM « Forecasted Cash December 31, 2005 = $25 - 30MM + Valuation Data 12.4 MM shares outstanding Post spin

Slide 17: Searchable text section of graphics shown above
Searchable text section of graphics shown above [ LOG O] Annual Meeting Princeton, New Jersey May 5th, 2005 [LOGO] For ward-Looking Statement When used anywhere in this presentation, the words “expects,” “believes,” “anticipates,” “estimates” and similar expressions are intended to identify forward-
Source: SEC EDGAR · 8-K filed May 5, 2005
More decks from Pharmacopeia Inc
Pharmacopeia — Merger or Acquisition (November 2008)34 slides · Nov 3, 2008
The Oppenheimer 19th Annual Healthcare Conference (November 2008)33 slides · Nov 3, 2008
Ligand Pharmaceuticals — Merger or Acquisition (September 2008)18 slides · Sep 24, 2008
BMO Capital Markets 7th Annual Focus on Healthcare Conference 200822 slides · Aug 5, 2008
Investor Presentation (May 2008)36 slides · May 19, 2008
Investor Presentation (May 2008)11 slides · May 16, 2008